
North America Veterinary API Market Size, Share & Industry Trends Analysis Report By Route of Administration, By API Type, By Synthesis Type, By Animal Type, By Country and Growth Forecast, 2023 - 2030
Description
North America Veterinary API Market Size, Share & Industry Trends Analysis Report By Route of Administration, By API Type, By Synthesis Type, By Animal Type, By Country and Growth Forecast, 2023 - 2030
The North America Veterinary API Market would witness market growth of 5.7% CAGR during the forecast period (2023-2030).
The production of veterinary active pharmaceutical ingredients entails the synthesis of APIs from basic materials using various high-tech processing techniques. Anti-infectives, vaccines, and nonsteroidal anti-inflammatory drugs are the principal products of veterinary active pharmaceutical ingredient production. It is expected that an increasing number of pet owners will drive the development of the market in the coming years. Pet proprietors are those who own or adopt a companion animal. The fact that pet owners provide essential health care for their animals increases the demand for veterinary medications.
The launch of biologically synthesized APIs is an advancement in technology that contributes to the expansion of the industry. In the future, veterinary biopharmaceuticals produced by rDNA technology will be a more viable option for treating diseases such as arthritis, cancer, and diabetes, as well as autoimmune disorders. In addition, introducing high-potency APIs (HPAPIs), which act on target cells at a much lower dosage than standard APIs, is anticipated to create lucrative possibilities for expansion in the market. The HPAPIs are causing significant alterations in the pharmaceutical industry's ability to develop novel therapeutic drugs.
In March 2022, Mainstreet Animal Hospital in Canada published an article on Primary Veterinary Care that discussed the numerous pet-related complications and their management. According to the article, old age significantly contributes to the advent of chronic diseases like osteoarthritis, heart disease, renal disease, endocrinological disorders, etc. The increasing prevalence of chronic diseases in veterinary animals and the need for appropriate medical management, such as the provision of effective medications for afflicted animals, are likely to drive market expansion in the region. Consequently, all of the factors above, such as the rise in pet ownership and the prevalence of chronic diseases in animals, are anticipated to bolster the regional market over the forecast period.
The US market dominated the North America Veterinary API Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3,286.9 million by 2030. The Canada market is experiencing a CAGR of 8.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 7.1% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Oral, Injectable, Topical and Others. Based on API Type, the market is segmented into Parasiticides, Anti-inflammatory, Antimicrobials, Vaccines, Hormones and Others. Based on Synthesis Type, the market is segmented into Chemical based API, Biological API and Highly potent API. Based on Animal Type, the market is segmented into Livestock Animals and Companion Animals. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Zoetis, Inc., Elanco Animal Health, Inc., Merck & Co., Inc., Virbac, Vetoquinol SA (Soparfin SCA), Sequent Scientific Limited, Phibro Animal Health Corporation, Febbrica Italina Sintetici S.P.A. (Nine Trees Group S.p.A) and Excel Industries Limited.
Scope of the Study
Market Segments covered in the Report:
By Route of Administration
- Oral
- Injectable
- Topical
- Others
- Parasiticides
- Anti-inflammatory
- Antimicrobials
- Vaccines
- Hormones
- Others
- Chemical based API
- Biological API
- Highly potent API
- Livestock Animals
- Companion Animals
- US
- Canada
- Mexico
- Rest of North America
- Boehringer Ingelheim International GmbH
- Zoetis, Inc.
- Elanco Animal Health, Inc.
- Merck & Co., Inc.
- Virbac
- Vetoquinol SA (Soparfin SCA)
- Sequent Scientific Limited
- Phibro Animal Health Corporation
- Febbrica Italina Sintetici S.P.A. (Nine Trees Group S.p.A)
- Excel Industries Limited
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
125 Pages
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 North America Veterinary API Market, by Route of Administration
- 1.4.2 North America Veterinary API Market, by API Type
- 1.4.3 North America Veterinary API Market, by Synthesis Type
- 1.4.4 North America Veterinary API Market, by Animal Type
- 1.4.5 North America Veterinary API Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market at a Glance
- 2.1 Key Highlights
- Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.3 Porter’s Five Force Analysis
- Chapter 4. Strategies Deployed in Veterinary API Market
- Chapter 5. North America Veterinary API Market by Route of Administration
- 5.1 North America Oral Market by Country
- 5.2 North America Injectable Market by Country
- 5.3 North America Topical Market by Country
- 5.4 North America Others Market by Country
- Chapter 6. North America Veterinary API Market by API Type
- 6.1 North America Parasiticides Market by Country
- 6.2 North America Anti-inflammatory Market by Country
- 6.3 North America Antimicrobials Market by Country
- 6.4 North America Vaccines Market by Country
- 6.5 North America Hormones Market by Country
- 6.6 North America Others Market by Country
- Chapter 7. North America Veterinary API Market by Synthesis Type
- 7.1 North America Chemical based API Market by Country
- 7.2 North America Biological API Market by Country
- 7.3 North America Highly potent API Market by Country
- Chapter 8. North America Veterinary API Market by Animal Type
- 8.1 North America Livestock Animals Market by Country
- 8.2 North America Companion Animals Market by Country
- Chapter 9. North America Veterinary API Market by Country
- 9.1 US Veterinary API Market
- 9.1.1 US Veterinary API Market by Route of Administration
- 9.1.2 US Veterinary API Market by API Type
- 9.1.3 US Veterinary API Market by Synthesis Type
- 9.1.4 US Veterinary API Market by Animal Type
- 9.2 Canada Veterinary API Market
- 9.2.1 Canada Veterinary API Market by Route of Administration
- 9.2.2 Canada Veterinary API Market by API Type
- 9.2.3 Canada Veterinary API Market by Synthesis Type
- 9.2.4 Canada Veterinary API Market by Animal Type
- 9.3 Mexico Veterinary API Market
- 9.3.1 Mexico Veterinary API Market by Route of Administration
- 9.3.2 Mexico Veterinary API Market by API Type
- 9.3.3 Mexico Veterinary API Market by Synthesis Type
- 9.3.4 Mexico Veterinary API Market by Animal Type
- 9.4 Rest of North America Veterinary API Market
- 9.4.1 Rest of North America Veterinary API Market by Route of Administration
- 9.4.2 Rest of North America Veterinary API Market by API Type
- 9.4.3 Rest of North America Veterinary API Market by Synthesis Type
- 9.4.4 Rest of North America Veterinary API Market by Animal Type
- Chapter 10. Company Profiles
- 10.1 Boehringer Ingelheim International Gmbh
- 10.1.1 Company Overview
- 10.1.2 Financial Analysis
- 10.1.3 Regional & Segmental Analysis
- 10.1.4 Research & Development Expenses
- 10.1.5 Recent strategies and developments:
- 10.1.5.1 Product Launches and Product Expansions:
- 10.1.5.2 Partnerships, Collaborations and Agreements:
- 10.1.6 SWOT Analysis
- 10.2 Zoetis, Inc.
- 10.2.1 Company Overview
- 10.2.2 Financial Analysis
- 10.2.3 Regional Analysis
- 10.2.4 Research & Development Expense
- 10.2.5 Recent strategies and developments:
- 10.2.5.1 Product Launches and Product Expansions:
- 10.2.5.2 Approvals and Trials:
- 10.2.5.3 Acquisition and Mergers:
- 10.2.6 SWOT Analysis
- 10.3 Elanco Animal Health, Inc.
- 10.3.1 Company Overview
- 10.3.2 Financial Analysis
- 10.3.3 Regional Analysis
- 10.3.4 Research & Development Expense
- 10.3.5 Recent strategies and developments:
- 10.3.5.1 Acquisition and Mergers:
- 10.3.6 SWOT Analysis
- 10.4 Merck & Co., Inc.
- 10.4.1 Company Overview
- 10.4.2 Financial Analysis
- 10.4.3 Segmental and Regional Analysis
- 10.4.4 Research & Development Expenses
- 10.4.5 Recent strategies and developments:
- 10.4.5.1 Geographical Expansions:
- 10.4.6 SWOT Analysis
- 10.5 Virbac
- 10.5.1 Company Overview
- 10.5.2 Financial Analysis
- 10.5.3 Regional Analysis
- 10.5.4 Recent strategies and developments:
- 10.5.4.1 Product Launches and Product Expansions:
- 10.5.5 SWOT Analysis
- 10.6 Vetoquinol SA (Soparfin SCA)
- 10.6.1 Company Overview
- 10.6.2 Financial Analysis
- 10.6.3 SWOT Analysis
- 10.7 Sequent Scientific Limited
- 10.7.1 Company Overview
- 10.7.2 Financial Analysis
- 10.7.3 Regional Analysis
- 10.7.4 SWOT Analysis
- 10.8 Phibro Animal Health Corporation
- 10.8.1 Company Overview
- 10.8.2 Financial Analysis
- 10.8.3 Segmental and Regional Analysis
- 10.8.4 Research & Development Expenses
- 10.8.5 SWOT Analysis
- 10.9 Febbrica Italina Sintetici S.P.A. (Nine Trees Group S.p.A)
- 10.9.1 Company Overview
- 10.9.2 Financial Analysis
- 10.9.3 Regional Analysis
- 10.10. Excel Industries Limited
- 10.10.1 Company Overview
- 10.10.2 Financial Analysis
- 10.10.3 Segmental Analysis
- 10.10.4 SWOT Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.